Active Composition: 24 mg/mL Monophasic Cross-linked Hyaluronic Acid (HA).

Anesthetic: 0.3% Lidocaine Hydrochloride (3 mg/mL).

Buffer: Phosphate buffer pH 7.2 q.s. (limits post-injection edema).

Formulation Technology: Proprietary VYCROSS™ Matrix.

Molecular Weight Ratio: 20% High Molecular Weight (>1000 kDa) / 80% Low Molecular Weight (<500 kDa).

Purity: Sterile, pyrogen-free (Endotoxin < 0.2 EU/).

Target Injection Depth: Mid-to-deep dermis (2.0mm – 4.0mm).

Clinical Duration: 9 to 12 months based on baseline metabolism.

Primary Indications: Perioral lines, superficial nasolabial folds, lip mucosal enhancement.

Tissue Integration: Retains 94% native tissue mobility at 30 days post-treatment.

Volume: 2 x 0.55 mL pre-filled, terminally sterilized glass.

Supplied: 2 x 27G 1/2″ (0.40 x 13 mm) sterile ultra-thin wall (TSK Laboratory).

Storage Conditions: 2°C to 25°C. Protect from freezing and direct light exposure.

Medical Disclaimer & E-E-A-T Compliance

This product is restricted to administration by licensed medical practitioners only. Strict contraindications exist for patients presenting with hypersensitivity to hyaluronic acid, lidocaine, or Gram-positive bacterial proteins. It is not indicated for intravascular injection. On-site anaphylaxis management protocols must be maintained. Product traceability relies on batch number verification via the manufacturer’s registry.